NCT02444182

Brief Summary

Some probiotics have been shown to have preventive effects on infectious diseases and allergies. Because their long-term enhancement of the immune responses of children, they have been recommended for infants in some countries. The most promising ones seem to be the combination of Bifidobacterium lactis BB-12 and Lactobacillus rhamnosus GG. Probiotic microbes are mainly ingested orally and the gastrointestinal tract is thus the primary target organ for them. However, the mouth is the first part of the gastrointestinal tract. Most probiotics are in theory cariogenic, thus their effects on oral health should be known. Several probiotics decrease levels of salivary mutans streptococci (MS), but in other respects very little is known about their effects on the oral microbiota. Also effects of probiotics on dental plaque should be studied. This study aims to find out the effects of the combination of BB-12 and LGG, delivered with a lozenge (4 weeks, twice a day) with a mixture of them on the amount of plaque and gingival health

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Dec 2014

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2014

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

May 12, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 14, 2015

Completed
18 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
10 months until next milestone

Results Posted

Study results publicly available

March 14, 2016

Completed
Last Updated

March 14, 2016

Status Verified

February 1, 2016

Enrollment Period

5 months

First QC Date

May 12, 2015

Results QC Date

November 16, 2015

Last Update Submit

February 16, 2016

Conditions

Outcome Measures

Primary Outcomes (2)

  • Gingival Health

    The gingival Index of Loe and Silness (1963) was used to record all surfaces (buccal, lingual, mesial, distal) for index teeth (16, 12, 24, 36, 32, 44). Gingival pockets were gently touched with a periodontal probe and possible bleeding was registered. The criteria are: 0 = no inflammation 1. = mild inflammation, slight change in color, slight edema, no bleeding on probing 2. = moderate inflammation, moderate glazing, redness, bleeding on probing 3. = severe inflammation, marked redness and hypertrophy, ulceration, tendency to spontaneous bleeding The GI of the tooth was determined by adding the scores of the four surfaces and divided the total by four. The GI of the individual was obtained by adding the values of each tooth and dividing by the number of teeth examined A score from 0.1-1.0 = mild inflammation; 1.1-2.0 = moderate inflammation, and 2.1-3.0 = severe inflammation

    Four weeks

  • Plaque Index

    A modified Quickley-Hein plaque index (PI) was used to record the buccal and lingual surfaces of all teeth (from right second molar to left second molar) 0 = no plaque 1. = separate flecks of plaque at the cervical margin of the tooth 2. = a thin continuous band of plaque at the cervical margin 3. = a band of plaque wider than 1 mm but covering less than 1/3 of the crown 4. = plaque covering at least 1/3 but less than 2/3 of the crown 5. = plaque covering 2/3 or more of crown An index for the entire mouth is determined by dividing the total score by the number surfaces (a maximum of 2 x 2 x 14 = 56 surfaces) examined. \*\* Plaque index score reported in the table below represents Pl for the entire mouth. the range is between 0 (no plaque) to 5 (maximum plaque coverage)

    four weeks

Study Arms (2)

Probiotics

EXPERIMENTAL

participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG

Dietary Supplement: Probiotics

Control - No probiotics

PLACEBO COMPARATOR

Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)

Dietary Supplement: Placebo

Interventions

ProbioticsDIETARY_SUPPLEMENT

A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted

Probiotics
PlaceboDIETARY_SUPPLEMENT

A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted

Control - No probiotics

Eligibility Criteria

Age13 Years - 15 Years
Sexmale
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Healthy Adolescent - ASA I \& II
  • No Antibiotics use
  • No intake of commercially available probiotics products during the intervention

You may not qualify if:

  • Adolescents have ASA III or IV
  • Antibiotics use
  • refuse to stop taking commercially available probiotics products during intervention

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Abdullah Alwaheeb intermediate School

Kuwait City, Kuwait, 13110, Kuwait

Location

Related Publications (1)

  • LOE H, SILNESS J. PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand. 1963 Dec;21:533-51. doi: 10.3109/00016356309011240. No abstract available.

MeSH Terms

Interventions

Probiotics

Intervention Hierarchy (Ancestors)

Dietary SupplementsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Limitations and Caveats

limitations of this study include: 1. short period: only 4 weeks to reach maximum compliance 2. number of participants: just above the minimum sample size due to refusal of many parents to give consent for their children participation.

Results Point of Contact

Title
Dr. Abrar Alanzi
Organization
Kuwait University - Faculty of Dentistry

Study Officials

  • ABRAR N ALANZI, MS

    KUWAIT UNIVERISTY

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
ASSISTANT PROFESSOR

Study Record Dates

First Submitted

May 12, 2015

First Posted

May 14, 2015

Study Start

December 1, 2014

Primary Completion

May 1, 2015

Study Completion

June 1, 2015

Last Updated

March 14, 2016

Results First Posted

March 14, 2016

Record last verified: 2016-02

Locations